| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 149, Issue 1 120-126, Copyright © 1992 by American Association of Immunologists
ARTICLES |
AJ Cumber, ES Ward, G Winter, GD Parnell and EJ Wawrzynczak
Drug Targeting Laboratory, Institute of Cancer Research, Sutton, U.K.
A murine antibody FvCys fragment with a single additional cysteine residue at the C terminus of the VH domain was expressed in Escherichia coli from a modified expression plasmid containing the structural genes for the VH and VL domains derived from the anti-lysozyme hybridoma D1.3. Chemical cross-linking between the introduced sulfhydryl groups of two FvCys fragments by means of bis-maleimidohexane was used to generate a bisFvCys conjugate. The stability of the bisFvCys conjugate and an FvCys analogue that had been reacted with N-ethyl-maleimide to block the free sulfhydryl group, FvCys(BL), were compared after 125I- labeling. The bisFvCys conjugate was completely stable to incubation in solution at 37 degrees C for 24 h whereas only 60% of the FvCys(BL) fragment remained soluble. After i.v. administration to normal Wistar rats, both Fv proteins were rapidly cleared from the circulation with biphasic kinetics that were best fitted to a two-compartment open pharmacokinetic model. The alpha-phase half-life of the bisFvCys conjugate, 0.32 h, was significantly longer than that of the FvCys(BL) fragment, 0.15 h (p less than 0.001) whereas there was no significant difference between the beta-phase half-lives, 1.4 to 1.6h. No chain cleavage or covalent attachment to serum protein was detected by SDS- PAGE analysis of serum samples. However, gel permeation HPLC revealed that both Fv proteins associated with serum proteins in vivo and in vitro.
This article has been cited by other articles:
|
|
 |
|
  Y.-P. Chen, Y.-Y. Qiao, X.-H. Zhao, H.-S. Chen, Y. Wang, and Z. Wang Rapid Detection of Hepatitis B Virus Surface Antigen by an Agglutination Assay Mediated by a Bispecific Diabody against Both Human Erythrocytes and Hepatitis B Virus Surface Antigen Clin. Vaccine Immunol., June 1, 2007; 14(6): 720 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Bera, J. Williams-Gould, R. Beers, P. Chowdhury, and I. Pastan Bivalent Disulfide-stabilized Fragment Variable Immunotoxin Directed against Mesotheliomas and Ovarian Cancer Mol. Cancer Ther., December 1, 2001; 1(2): 79 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schmiedl, F. Breitling, and S. Dubel Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli Protein Eng. Des. Sel., October 1, 2000; 13(10): 725 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vallera, D. W. Kuroki, A. Panoskaltsis-Mortari, D. J. Buchsbaum, B. E. Rogers, and B. R. Blazar Molecular modification of a recombinant anti-CD3epsilon -directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model Blood, August 1, 2000; 96(3): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Carrero, W. D. Mallender, and E. W. Voss Jr. Anti-metatype Antibody Stabilization of Fv 4-4-20 Variable Domain Dynamics J. Biol. Chem., May 10, 1996; 271(19): 11247 - 11252. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
